Publish Date: 27 January 2013 - 23:42

Despite its claims of easing the restrictions on the sales of medicine to Iran, Washington has launched an investigation into the transactions of Switzerland’s biggest pharmaceutical company, Novartis, with the Islamic Republic.

In its 2012 annual report, Novartis said its Alcon eye-care unit is being investigated by the United States for exporting medicine to Iran, Wall Street Journal reported.

Alcon received a subpoena in 2012 from the US attorney's office for the Northern District of Texas, seeking documents related to its exports to Iran that date back to 2005, years before the current sanctions were enacted.


This is while the US Treasury Department said in October 2012 that American companies are allowed to sell certain medicines and basic medical supplies to Iran without first seeking a license from the Office of Foreign Assets Control.

The move was made amid Iran’s protests that the US-engineered sanctions were hurting ordinary Iranian citizens and over fears that the humanitarian effects of the unilateral sanctions could undermine support for the bans among Washington’s allies.

According to US rules, exporters of medicine and medical supplies to Iran are required to apply for special licenses. Besides, as the aftermath of the sanctions, the impossibility of transferring money through banks has cast its cumbersome shadow upon medicine and healthcare in Iran and has gravely affected the import of medicines to Iran.

On January 26, in a second letter to UN Secretary General Ban Ki-Moon, President of Academy of Medical Sciences Dr. Seyed Alireza Marandi criticized him for his silence and indifference to the threats directed at the health of Iranian people and urged him to show real action.

“As the individual responsible for surveying and monitoring national health related issues, I affirm that this problem is real and the current situation was predictable from the start of the brutal sanctions,” Marandi said in his letter.

At the beginning of 2012, the United States and the European Union imposed sanctions on Iran’s oil and financial sectors with the goal of preventing other countries from purchasing Iranian oil and conducting transactions with the Central Bank of Iran. The sanctions entered into force in early summer 2012.

On October 15, the EU foreign ministers reached an agreement on another round of sanctions against Iran.

The illegal US-engineered sanctions were imposed based on the accusation that Iran is pursuing non-civilian objectives in its nuclear energy program.

Iran rejects the allegations, arguing that as a committed signatory to nuclear Non-Proliferation Treaty (NPT) and a member of International Atomic Energy Agency (IAEA), it has the right to use nuclear technology for peaceful purposes.
irna/281